Lenz & Staehelin advised Asceneuron in its Series C financing. Asceneuron SA, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a root...
Asceneuron SA’s $100 Million Series C Financing Round
Ferrer’s Progressive Supranuclear Palsy (PSP) License Agreement with Asceneuron
Lenz & Staehelin advised Asceneuron in this transaction. Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron have announced the signing of a licensing...